1
|
Sarigul E, Zaim M, Senel M, Sagir T, Isik S. Polyamidoamine Dendron-Bearing Lipids as Drug-Delivery Excipients. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27227817. [PMID: 36431916 PMCID: PMC9697672 DOI: 10.3390/molecules27227817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 11/09/2022] [Accepted: 11/11/2022] [Indexed: 11/16/2022]
Abstract
An amine-terminated polyamidoamine (PAMAM) dendron and two long alkyl groups were designed as a novel drug carrier that possesses an interior for the encapsulation of drugs and a biocompatible surface. We synthesized three dendron-bearing lipids, DL-G1, DL-G2, and DL-G3, which included first, second, and third generation polyamidoamine dendrons, respectively. The synthesized dendrimer encapsulating anticancer drug, 5-fluorouracil (5-FU), was prepared by extraction with chloroform from mixtures of the dendrimers and varying amounts of the drug. In vitro cytotoxicity of PAMAM conjugated di-n-dodecylamine micelles (G1, G2, G3) were analyzed on human gastric adenocarcinoma cells (AGS) by water-soluble tetrazolium-1 (WST-1) cell proliferation assay. Upon exposure to 5-FU loaded micelles, the viability of the cells decreased gradually in all generations. Cytotoxicity increased with increasing generation and reached its highest rate of 69.8 ± 3.2% upon 15 µM 5FU-loaded 25 µM PAMAM DL-3 micelle treatment. These results demonstrate that 5FU-loaded PAMAM conjugated di-n-dodecylamine treatment inhibits the proliferation of AGS cells in a generation-dependent manner.
Collapse
Affiliation(s)
| | - Merve Zaim
- SANKARA Brain and Biotechnology Research Center, Avcilar, Istanbul 34320, Turkey
| | - Mehmet Senel
- Department of Biochemistry, Faculty of Pharmacy, Biruni University, Istanbul 34010, Turkey
- Correspondence: or (M.S.); or (S.I.)
| | - Tugba Sagir
- Pim Grup Cosmetics Consultancy, Gokturk, Istanbul 34077, Turkey
| | - Sevim Isik
- Department of Molecular Biology and Genetics, Faculty of Science and Engineering, Uskudar University, Uskudar, Istanbul 34662, Turkey
- Correspondence: or (M.S.); or (S.I.)
| |
Collapse
|
2
|
Ahmad N, Albassam AA, Faiyaz Khan M, Ullah Z, Mohammed Buheazah T, Salman AlHomoud H, Ali Al-Nasif H. A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer. Saudi J Biol Sci 2022; 29:3704-3716. [PMID: 35844373 PMCID: PMC9280251 DOI: 10.1016/j.sjbs.2022.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 01/20/2022] [Accepted: 02/13/2022] [Indexed: 11/18/2022] Open
Abstract
5-Fluorouracil (5-FU) is a drug of choice for colorectal-cancer. But oral therapeutic efficacy of 5-FU is restricted due to their very little bioavailability because of poor membrane permeability and GIT-absorption. We have developed a multiple nanoemulsion (w/o/w i.e. 5-FU-MNE) in which 5-FU incorporated to improve their oral-absorption. Globule-size of opt-5-FU-MNE was 51.64 ± 2.61 nm with PDI and ZP 0.101 ± 0.001 and −5.59 ± 0.94, respectively. In vitro 5-FU-release and ex vivo permeation studies exhibited 99.71% release and 83.64% of 5-FU from opt-nanoformulation. Cytotoxic in vitro studies-exhibited that 5-FU in opt-5-FU-MNE was 5-times more potent than 5-FU-S on human-colon-cancer-cell-lines (HT-29). The enhanced Cmax with AUC0-8h with opt-5-FU-MNE was shown extremely significant (p < 0.001) in wistar rat’s plasma in the comparison of oral and i.v. treated group of 5-FU-S by PK-observations. Furthermore, opt-5-FU-MNE was showed much more significant (p < 0.001) results as compared to 5-FU-S (free) on cell lines for human colon cancer (HT-29).
Collapse
|
3
|
Alanazi SA, Harisa GI, Badran MM, Haq N, Radwan AA, Kumar A, Shakeel F, Alanazi FK. Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition. Curr Drug Deliv 2020; 17:898-910. [PMID: 32072911 DOI: 10.2174/1567201817666200211095452] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 11/13/2019] [Accepted: 01/20/2020] [Indexed: 11/22/2022]
Abstract
Purpose:
Hepatocellular carcinoma (HCC) is a common liver malignancy, which has a low
survival rate of all cancers. 5-fluorouracil (5-FU) is clinically recognized to treat HCC. However, the
success of this therapy is highly limited due to rapid clearance and non- selective distribution. Cholesterol-
conjugate (5-FUC) loaded liposomes proposed to facilitate the transport of 5-FUC into tumor cells
via Low-Density Lipoprotein receptor (LDL receptor) that overexpressed in HCC. Thus, the aim of this
study was to use 5-FUC loaded liposome as a promising strategy to combat HCC and improve the response
of HCC to chemotherapy.
Methods:
5-FUC and 5-FU loaded liposomes were optimized based on Cholesterol (CHO) ratio and
type of phospholipid to achieve a potential effect on HCC. Liposomes were prepared by the thin-film
hydration method, and evaluated in terms of particle size, polydispersity, zeta potential, Entrapment
Efficiency (EE), morphology, drug release and cytotoxicity.
Results:
The obtained liposomes had a suitable nano-range particle size with negative zeta potential,
and acceptable EE%. In vitro drug release of 5-FUC loaded liposomes showed a lower cumulative release
over 24 h as compared to 5-FU loaded liposomes. 5-FUC loaded liposomes exhibited a higher in
vitro cytotoxic effect as compared to the free drug and 5-FU loaded liposomes against HepG2 cell lines
after 48 h via MTT assay.
Conclusion:
These results concluded that 5-FUC loaded liposomes could be used as an alternative tactic
to increase the therapeutic index of 5-FU and pave the way for potential clinical applications.
Collapse
Affiliation(s)
- Saleh Ayed Alanazi
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Gamaleldin Ibrahim Harisa
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Mohammad M. Badran
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Nazrul Haq
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Awwad Abdoh Radwan
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Ashok Kumar
- Vitiligo Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Faiyaz Shakeel
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Fars Kaed Alanazi
- Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
4
|
The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology. Cancers (Basel) 2020; 12:cancers12092712. [PMID: 32971780 PMCID: PMC7563483 DOI: 10.3390/cancers12092712] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 09/11/2020] [Accepted: 09/17/2020] [Indexed: 12/30/2022] Open
Abstract
Simple Summary New clinical radiology scans using trace amounts of therapeutic cancer drugs labeled with radioisotope injected into patients can provide oncologists with fundamentally unique insights about drug delivery to tumors. This new application of radiology aims to improve how cancer drugs are used, towards improving patient outcomes. The article reviews published clinical research in this important new field. Abstract Translational development of radiolabeled analogues or isotopologues of small molecule therapeutic drugs as clinical imaging biomarkers for optimizing patient outcomes in targeted cancer therapy aims to address an urgent and recurring clinical need in therapeutic cancer drug development: drug- and target-specific biomarker assays that can optimize patient selection, dosing strategy, and response assessment. Imaging the in vivo tumor pharmacokinetics and biomolecular pharmacodynamics of small molecule cancer drugs offers patient- and tumor-specific data which are not available from other pharmacometric modalities. This review article examines clinical research with a growing pharmacopoeia of investigational small molecule cancer drug tracers.
Collapse
|
5
|
Pharmacokinetic and in vitro cytotoxic evaluation of cholesterol-rich nanoemulsion of cholesteryl-succinyl-5-fluorouracil. J Mol Liq 2015. [DOI: 10.1016/j.molliq.2015.06.069] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
6
|
Alanazi FK, Haq N, Radwan AA, Alsarra IA, Shakeel F. Development and validation of UHPLC-DAD method for the determination of cholesteryl-hexahydrophthaloyl-5-fluorouracil in lipid nanoemulsion. JOURNAL OF ANALYTICAL CHEMISTRY 2015. [DOI: 10.1134/s1061934815050056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Potential of lipid nanoemulsion for drug delivery of cholesteryl-hexahydrophthaloyl-5-fluorouracil. J Drug Deliv Sci Technol 2014. [DOI: 10.1016/s1773-2247(14)50088-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
8
|
Alanazi FK, Haq N, Radwan AA, Alsarra IA, Shakeel F. Formulation and evaluation of cholesterol-rich nanoemulsion (LDE) for drug delivery potential of cholesteryl-maleoyl-5-fluorouracil. Pharm Dev Technol 2013; 20:266-70. [PMID: 24266739 DOI: 10.3109/10837450.2013.860551] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
Improved stability and tumor targeting of 5-fluorouracil by conjugation with hyaluronan. J Appl Polym Sci 2013. [DOI: 10.1002/app.39247] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
10
|
Srinivas M, Boehm-Sturm P, Figdor CG, de Vries IJ, Hoehn M. Labeling cells for in vivo tracking using 19F MRI. Biomaterials 2012; 33:8830-40. [DOI: 10.1016/j.biomaterials.2012.08.048] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Accepted: 08/22/2012] [Indexed: 12/11/2022]
|
11
|
McIntyre DJO, Madhu B, Lee SH, Griffiths JR. Magnetic resonance spectroscopy of cancer metabolism and response to therapy. Radiat Res 2012; 177:398-435. [PMID: 22401303 DOI: 10.1667/rr2903.1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Magnetic resonance spectroscopy allows noninvasive in vivo measurements of biochemical information from living systems, ranging from cultured cells through experimental animals to humans. Studies of biopsies or extracts offer deeper insights by detecting more metabolites and resolving metabolites that cannot be distinguished in vivo. The pharmacokinetics of certain drugs, especially fluorinated drugs, can be directly measured in vivo. This review briefly describes these methods and their applications to cancer metabolism, including glycolysis, hypoxia, bioenergetics, tumor pH, and tumor responses to radiotherapy and chemotherapy.
Collapse
Affiliation(s)
- Dominick J O McIntyre
- Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
| | | | | | | |
Collapse
|
12
|
|
13
|
Kaestner SA, Sewell GJ. Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area. Clin Oncol (R Coll Radiol) 2007; 19:23-37. [PMID: 17305252 DOI: 10.1016/j.clon.2006.10.010] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Cytotoxic chemotherapy is characterised by a low therapeutic index and significant variability in therapeutic and toxic effects. In an attempt to reduce this variability, most chemotherapy doses are individualised according to patient body surface area (BSA). This practice, which was introduced almost 50 years ago, clearly has practical and economic implications for the healthcare system. Furthermore, the clinical value of this approach has, in recent years, been questioned. Despite established practice, chemotherapy dose selection remains complicated, partly because treatment effects are difficult to measure, partly because drugs are used in combination with other treatment modalities, and also because the patient's condition may change with disease progression. Various patient-related factors can affect drug pharmacokinetics (PK) and pharmacodynamics (PD), for example organ function, expression and activity of metabolising enzymes, drug resistance, body size, gender, age, concomitant disease and co-administration of other drugs. These factors may be of clinical significance in chemotherapy dose determination and measures of PK, PD or both feature in attempts to devise more rigorous methods for chemotherapy dosing. Part I of this series of two reviews describes the history and clinical impact of BSA-based chemotherapy, and examines the scientific evidence to support BSA dosing. It evaluates the factors affecting PK and PD for specific drugs that could inform and refine dose determination.
Collapse
Affiliation(s)
- S A Kaestner
- Department of Pharmacy and Pharmacology, 5W, University of Bath, Claverton Down, Bath BA2 7AY, UK
| | | |
Collapse
|
14
|
van Laarhoven HWM, Punt CJA, Kamm YJL, Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy. Crit Rev Oncol Hematol 2005; 56:321-43. [PMID: 15982898 DOI: 10.1016/j.critrevonc.2005.03.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2004] [Revised: 03/21/2005] [Accepted: 03/21/2005] [Indexed: 01/18/2023] Open
Abstract
(19)Fluorine magnetic resonance spectroscopy ((19)F MRS) offers unique possibilities for monitoring the pharmacokinetics of fluoropyrimidines in vivo in tumors and normal tissue in a non-invasive way, both in animals and in patients. This method may therefore be useful for predicting response to fluoropyrimidine-based therapy with or without the effects of modulating agents, and this may be of value for the individualization of anticancer therapy and the strategic development of new anticancer drugs. (19)F MRS has been very valuable in elucidating the basic aspects of fluoropyrimidine metabolism, especially in animal studies. Studies in humans have indicated its clinical potential, but widespread application has been hampered by the relatively low detection sensitivity of the method. The recent introduction of clinical MR scanners with magnetic fields above 1.5 T may stimulate increased clinical use of (19)F MRS.
Collapse
Affiliation(s)
- Hanneke W M van Laarhoven
- Department of Medical Oncology 550, University Medical Centre Nijmegen, P.O. Box, 9101 HB, Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|